Quantcast

Latest Peptides Stories

2009-12-17 09:17:00

BASKING RIDGE, N.J., Dec. 17 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic therapeutic aptamers with active control agents, today announced the completion of a $40 million Series D financing. The round, led by new investor Edmond de Rothschild Investment Partners, part of The LCF Rothschild Group, was joined by existing investors Domain Associates, Quaker Bioventures, Aurora Funds, Caxton Advantage Life Sciences Fund and other...

2009-12-09 14:04:32

Approximately 20 percent of dialysis patients undergoing a percutaneous coronary intervention (PCI; procedure such as angioplasty) are given an antithrombotic medication they should not receive, which may increase their risk for in-hospital bleeding, according to a study in the December 9 issue of JAMA. "In the United States, medication errors are implicated in more than 100,000 deaths annually. Medication errors include adverse drug reactions related to inappropriately prescribed or...

2009-12-07 09:00:00

NEW YORK, Dec. 7 /PRNewswire/ -- In an effort to heighten awareness and further educate the medical community about the importance of glutathione, Kyowa Hakko USA is sponsoring a special glutathione workshop entitled, Absorption of Oral Glutathione and Implications for Human Health, at the 17th Annual World Congress on Anti-Aging Medicine (A4M) in Las Vegas, Thursday, December 10, 6-8 p.m. in the South Pacific Ballroom I at the Mandalay Bay Resort and Convention Center. To RSVP for the free...

2009-11-30 15:19:56

Finding and treating a tumor without disturbing normal tissue presents challenges "“ sometimes the most effective therapies can be invasive and harsh. Researchers at Duke University Medical Center have devised a way they might deliver the right therapy directly to tumors using special molecules, called aptamers, which specifically bind to living tumor tissue. They screened a large pool of aptamers in a rodent with liver cancer until they found the best molecule to bind to a tumor...

2009-11-25 09:21:00

BASKING RIDGE, N.J., Nov. 25 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David Mazzo, PhD, CEO and President, will be presenting at the Piper Jaffray 21st Annual Health Care Conference at the New York Palace Hotel in New York City. Dr. Mazzo's presentation will be given at 1:10pm (EST) on Tuesday, December 1 and will include an overview of the Company's pipeline with emphasis on...

2009-11-12 08:36:00

BASKING RIDGE, N.J., Nov. 12 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David Mazzo, PhD, CEO and President, will be presenting at the Lazard Capital Markets 6th Annual Healthcare Conference at the St. Regis Hotel in New York City. Dr. Mazzo's presentation will be given at 1:10pm (EST) on Tuesday, November 17 and will include an overview of the Company's pipeline with emphasis on...

2009-11-11 08:15:00

SAN MARCOS, Calif., Nov. 11 /PRNewswire-FirstCall/ -- Natural Alternatives International, Inc. ("NAI")(Nasdaq: NAII), today announced that it has filed a lawsuit in the U.S. District Court for the District of Delaware, accusing Vital Pharmaceutical, Inc. ("VPX") and DNP International Co., Inc. of infringing patents exclusively licensed to NAI relating to its CarnoSyn® beta-alanine. NAI has also asserted claims for unfair competition and false marking against one or both...

2009-11-11 08:00:00

BASKING RIDGE, N.J., Nov. 11 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Chris Rusconi, PhD, Senior Vice President and Chief Scientific Officer, will be presenting an abstract at Biotech 2009 held at the Pennsylvania Convention Center in Philadelphia, Pennsylvania. Dr. Rusconi's abstract "Aptamer-Active Control Agent Pairs as a Discovery Platform for the Generation of Safer...

2009-11-10 08:00:00

BASKING RIDGE, N.J., Nov. 10 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Ellen McDonald, MBA, Senior Vice President and Chief Business Officer, will be presenting at Biotech 2009 held at the Pennsylvania Convention Center in Philadelphia, Pennsylvania. Ms. McDonald's presentation will be given at 10:15am (EST) on Monday, November 16 and will include an overview of...

2009-11-03 08:24:00

BASKING RIDGE, N.J., Nov. 3 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced today that David J. Mazzo, Ph.D., President and Chief Executive Officer, will be presenting at the 3rd Annual Canaccord Adams Cardiovascular Conference at the Nikko Hotel in San Francisco, California. Dr. Mazzo's presentation scheduled for Tuesday, November 10, 2009 at 1:30 PM (PST), will include an overview of the...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related